The Indian government has approved a new Essential Drug List which increases the number of drugs included in the list and will therefore be subjected to a price-cap. The move will curtail prices of costly brands sold by both domestic and international drug-makers in a market that already has rock-bottom medicine prices which makes experts sceptical about the benefits of this policy. Instead of 74 drugs 348 essential medicines' prices will be regulated by the Ministry. Valued around $13 billion India’s domestic drug market is the fourth largest in the world by volume. Abbot Laboratories Cipla and Sun Pharma are
